Refine by
Immunotherapy Treatment Suppliers & Manufacturers
26 companies found
based inSacramento, CALIFORNIA (USA)
We are a next-generation biotechnology company creating an AI-powered platform for custom protein design. Our platform develops Novobinders: proprietary protein binders with diagnostic and therapeutic applications. AINovo Biotech works with select ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
based inNottingham, UNITED KINGDOM
Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based ...
Oncimmune’s proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers that can help stratify patients in multiple cancer indications and with different autoimmune ...
based inPrinceton, NEW YORK (USA)
We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers. Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel ...
UGN-301 is UroGen’s in-licensed anti-CTLA-4 antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist. When combined, these medicines stimulate both the innate (UGN-201) and adaptive ...
based inHergiswil, SWITZERLAND
BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology. Our company focuses on the development of ...
Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno ...
based inParis, FRANCE
Inovarion is a research center in Life Sciences which has established itself in a few years as a key player in research and development in France. Through its talents, the Inovarion research center develops in-house research projects and guides its ...
The latest advances in cancerology have made it possible to dissect the complexity of the signaling pathways leading to cancerous pathologies. New lines of thought have thus been drawn up in terms of therapies and tumor characterization. The ...
based inMölndal, SWEDEN
Alzinova AB is a Swedish clinical-stage biopharma company pioneering the development of an active immunotherapy against Alzheimer’s disease. The vaccine is in clinical development and tested in patients. The company’s shares (ALZ) are listed on ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type. We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
based inLeiden, NETHERLANDS
Founded in 1959, HAL Allergy started as a small laboratory in Haarlem, the Netherlands. On request of several local general practitioners, extracts were prepared on a named patient basis to treat allergic reactions. Ever since the core business of ...
High prevalence rates illustrate the relevance of allergic research, An unmet need for novel targeted medicines that treat the underlying cause of allergic rhinitis and asthma still does exist. Until now allergen immunotherapy is ...
based inBuffalo, NEW YORK (USA)
Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor ...
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few ...
based inOlathe, KANSAS (USA)
TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved ...
TVAX®’s second candidate (TVI-Kidney-1) is being evaluated for the treatment of kidney cancer and targets stage 4 renal cell ...
based inMorrisville, NORTH CAROLINA (USA)
Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy ...
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic cells), and T cells—but ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
Food allergy has become a significant health problem with increasing incidence and severity, particularly in children but continuing throughout adulthood. There is no cure for food allergy, and allergic reactions can be life threatening. According ...
based inIllkirch-Graffenstaden, FRANCE
Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for ...
based inNew York, NEW YORK (USA)
Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and ...
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that ...
based inNanjing, CHINA
Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, ...
based inHouston, TEXAS (USA)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived ...
Cancer Immunotherapies are a New Method of Cancer Treatment. Among the more established treatment options, such as surgery, chemotherapy, targeted therapy, and radiation therapy, cancer ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore ...